In a 2-year longitudinal study of 28 levodopa‑naïve Parkinson's patients, women had significantly higher levodopa AUC and Cmax than men, and in women (but not men) higher exposure correlated with greater wearing‑off and dyskinesia.
Provides clinically actionable evidence that sex-specific levodopa pharmacokinetics predispose women to motor complications, supporting early plasma monitoring and sex‑adjusted dosing to reduce levodopa-related adverse effects and personalize therapy.